Phase 3 trial in 160 patients with untreated non-squamous NSCLC and brain metastases: bevacizumab plus pemetrexed-platinum gave longer median intracranial PFS than pemetrexed-platinum (11.07 vs 7.37 months; HR 0.494). Median OS difference was not significant.
RCTn = 160
Li et al. Bevacizumab plus chemotherapy versus chemotherapy in untreated advanced non-squamous non-small-cell lung cancer patients with brain metastases (BAP BRAIN): an open-label, randomized, multicenter, phase III study